ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF Drugs"

  • Abstract Number: 1326 • ACR Convergence 2020

    Malignancy Risk Among Patients with Ankylosing Spondylitis in the United States: A Population-Based National Study

    Sali Merjanah1, Mohamad Bittar2 and Marina Magrey3, 1Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, 2The University of Tennessee Health Science Center, Memphis, TN, 3Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Increased cancer risk has been reported with Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), but the correlation is poorly studied in Ankylosing spondylitis…
  • Abstract Number: 1873 • ACR Convergence 2020

    The Changing Profile of Ankylosing Spondylitis in the Biologic Era

    Lauren Ridley1, Michael Weisman2, Lianne Gensler3, Michael Ward4, Mark Hwang5, Amirali Tahanan6, MinJae Lee7, Mohammad Rahbar6, Mariko Ishimori8, Matthew Brown9 and John Reveille10, 1McGovern Medical School at UTHealth, Houston, TX, 2Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3University of California San Francisco, San Francisco, CA, 4National Institutes of Health, Bethesda, MD, 5McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, 6McGovern Medical School at UTHealth, Houston, 7UT Southwestern, Dallas, 8Cedars-Sinai Medical Center, Los Angeles, CA, 9Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, 10Department of Internal Medicine, University of Texas, Houston, TX

    Background/Purpose: To compare disease characteristics, comorbidities, and medication utilization of 573 patients with ankylosing spondylitis (AS) with short (< 20 years) disease duration (from symptom…
  • Abstract Number: 0227 • ACR Convergence 2020

    Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors

    Lucía Vega-Álvarez1, Itziar Calvo-Zorrilla1, Oihane Ibarguengoitia-Barrena1, Juan M. Blanco-Madrigal1, David Montero-Seisdedos2, Carmen L. Garcia-Gomez1, Maria Esther Ruiz-Lucea1, Ana R. Inchaurbe-Pellejero1, Ignacio Torre-Salaberri1, Clara E. Perez-Velasquez1, Olaia Fernandez-Berrizbeitia1, Eduardo Cuende-Quintana3, Iñigo R. Gorostiza-Hormaetxe4, María Luz García-Vivar1 and Eva Galindez-Agirregoikoa1, 1Basurto University Hospital, BILBAO, Spain, 2Basurto University Hospital, Bilbao, Pais Vasco, Spain, 3Basurto University Hospital, Madrid, Spain, 4Basurto University Hospital, Bilbao

    Background/Purpose: Infections are one of the main complications among patients with rheumatoid arthritis (RA) with immunosuppressive treatment. The differences between treatments and the influence of…
  • Abstract Number: 0754 • ACR Convergence 2020

    The Association Between Continuous Decreases in Serum RF Titers and Radiographic Remission of Joint Damage in RA Patients Treated with Biological or Targeted Synthetic DMARDs

    Takayoshi Owada1, Ayae Tanaka2, Hirokuni Hirata1, Masafumi Arima3, Yasutsugu Fukushima1 and Kazuhiro Kurasawa3, 1Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, 2Dokkyo Medical University, Shimotsuga-Gun, Japan, 3Dokkyo Medical University, Mibu, Shimotsugagun, Tochigi, Japan

    Background/Purpose: Rheumatoid factors (RFs) are RA-related autoantibodies like anti-cyclic citrullinated peptide antibodies, and are used for classifying and diagnosing RA. In addition, positivity and high…
  • Abstract Number: 1342 • ACR Convergence 2020

    Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK

    Filip Van den Bosch1, Peter Nash2, James Cheng-Chung Wei3, Francisco Blanco4, Vassilis Tsekouras5, Chuanbo Zang6, Daniela Graham7, Edmund Arthur8, Pamela Selema6, Bonnie Vlahos6 and Atul Deodhar9, 1Ghent University Hospital, Ghent, Belgium, 2School of Medicine Griffith University, Brisbane, Queensland, Australia, 3Chung Shan Medical University Hospital, Taichung, Taiwan (Republic of China), 4INIBIC-Complejo Hospitalario Universitario A Coruña, A Coruna, Spain, 5Pfizer, Nicosia, Cyprus, 6Pfizer, Collegeville, PA, 7Pfizer, Groton, PA, 8Pfizer, Peapack, NJ, 9Oregon Health & Science University, Portland, OR

    Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…
  • Abstract Number: 1965 • ACR Convergence 2020

    Reducing Delays for Biologic Medication Approval in Outpatient Rheumatology

    Josh Waytz1, Dahlia Sultan1 and Veena Patel2, 1University of Chicago, Chicago, IL, 2Dell Medical School - UT Health Austin, Austin, TX

    Background/Purpose: Biologic medications are commonly used for numerous rheumatologic conditions. A significant proportion of these medications are denied for non-medical reasons by insurance companies causing…
  • Abstract Number: 0240 • ACR Convergence 2020

    Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures

    Roy Fleischmann1, Karina Maslova2, Henry Leher3, Amy Praestgaard2 and Gerd Burmester4, 1Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Sanofi, Cambridge, MA, 3Regeneron Pharmaceuticals, Inc, Tarrytown, NY, 4Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: A proportion of adult patients with RA are refractory to TNF inhibitors (TNFi), and treatment with subsequent biologics may be associated with reduced response.…
  • Abstract Number: 0798 • ACR Convergence 2020

    A Randomized, Double-blind Phase 3 Study Comparing the Efficacy, Safety and Immunogenicity of PF-06410293 (Abrilada™), an Adalimumab (ADL) Biosimilar, and Reference ADL (Humira®) in Patients with Moderate to Severe Active RA: Results from Weeks 52-92

    Roy Fleischmann1, Daniel Alvarez2, Amy Bock3, Carol Cronenberger4, Ivana Vranic5, Wuyan Zhang6 and Rieke Alten7, 1Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, 2Pfizer, Collegeville, PA, 3Pfizer, Cambridge, MA, 4Pfizer, Collegeville, 5Pfizer, Tadworth, United Kingdom, 6Pfizer, New York, 7Schlosspark-Klinik, Universitätsmedizin, Berlin, Germany

    Background/Purpose: To evaluate the long-term safety, immunogenicity (IG), and efficacy of the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF), in patients (pts) with moderate to severe active…
  • Abstract Number: 1347 • ACR Convergence 2020

    Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study

    Walter Maksymowych1, Thomas Kumke2, Simone Auteri3, Bengt Hoepken2, Lars Bauer2 and Martin Rudwaleit4, 1University of Alberta, Edmonton, AB, Canada, 2UCB Pharma, Monheim am Rhein, Germany, 3UCB Pharma, Milan, Italy, 4Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany

    Background/Purpose: Identification of predictive clinical factors of long-term treatment response in non-radiographic axial spondyloarthritis (nr-axSpA) may contribute to improved management of patients with this chronic…
  • Abstract Number: 2004 • ACR Convergence 2020

    Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients

    Chary Lopez-Pedrera1, Maria Luque-Tevar1, Carlos Pérez-Sánchez1, Pilar Font2, Alejandra Maria Patiño-Trives1, Iván Arias de la Rosa1, María-Carmen Abalos-Aguilera1, Carmen Torres-Granados1, Montserrat Romero-Gomez2, Desirée Ruiz-Vilchez2, Rafaela Ortega-Castro3, Alejandro Escudero-Contreras4, Carlos Rodriguez-Escalera5, Jose Perez-Venegas6, Mª Dolores Ruiz-Montesinos6, Carmen Dominguez6, Carmen Romero-Barco7, Antonio Fernandez-Nebro8, Natalia Mena-Vazquez9, Jose Luis Marenco10, Julia Uceda-Montañez10, Mª Dolores Toledo-Coello11, Nuria Barbarroja4, M Angeles Aguirre2 and Eduardo Collantes2, 1Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 2Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 3Hospital Universitario Reina Sofía, Córdoba, Spain, 4IMIBIC/Hospital Reina Sofia /Universidad de Cordoba., Córdoba, Spain, 5Hospital Universitario de Jaen, Jaén, Spain, 6Hospital Universitario Virgen Macarena, Sevilla, Sevilla, Spain, 7Hospital Clínico Universitario, Málaga, Málaga, Spain, 8University of Malaga, Malaga, Spain, 9Hospital Regional Universitario de Málaga, Málaga, Spain, 10Hospital Universitario Virgen de Valme, Sevilla, Sevilla, Spain, 11Hospital Universitario de Jerez de la Frontera, Cádiz, Spain, Cádiz, Spain

    Background/Purpose: To evaluate changes produced in circulating inflammatory mediators and their regulatory miRNAs in RA patients after 3 and 6 months of treatment with TNF-α inhibitors…
  • Abstract Number: 0348 • ACR Convergence 2020

    Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study

    Philippe Bertin1, Philippe Goupille2, Florence Tubach3, Eric Lespessailles4, Naoual Harid5, Saannya Sequeira6, Jean-Marie Fayette6, Bruno Fautrel7 and Rene-Marc Flipo8, 1Limoges University Hospital, Limoges, France, 2CHU Tours, department of rheumatology, Tours, France, 3Pierre Louis Institute of Epidemiology and Public Health, INSERM 1136, Sorbonne University and Centre of Pharmacoepidemiology, Pitié Salpêtrière Hospital, APHP.Sorbonne University, Paris, Ile-de-France, France, 4Regional Hospital and University of Orleans, Orléans, France, 5MSD France Puteaux, Puteaux, Ile-de-France, France, 6ClinSearch, Malakoff, Ile-de-France, France, 7Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, 8Lille University Hospital, Lille, France

    Background/Purpose: Golimumab (GLM) is the latest anti-TNFα to be indicated for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The post-registration GO-PRACTICE…
  • Abstract Number: 0800 • ACR Convergence 2020

    A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

    Jonathan Kay1, Janusz Jaworski2, Rafal Wojciechowski3, Piotr Wiland4, Anna Dudek5, Marek Krogulec6, Slawomir Jeka7, Agnieszka Zielinska8, Jakub Trefler9, Katarzyna Bartnicka-Maslowska10, Magdalena Krajewska-Wlodarczyk11, Piotr Klimiuk12, Daniel Furst*13, SangJoon Lee14, YunJu Bae14, GoEun Yang14, JaeKyoung Yoo14, HyunJin Lee14 and Edward C Keystone15, 1University of Massachusetts Medical School, Worcester, MA, 2Reumatika-Centrum Reumatologii, Warsaw, Poland, 3University Hospital No 2, Bydgoszcz, Poland, 4Medical Univeristy, Wroclaw, Poland, 5Centrum Medyczne AMED, Warsaw, Poland, 6Rheumatology Clinic NZOZ Lecznica MAK-MED, Nadarzyn, Poland, 72nd Univ Hospital, CM UMK, Bydgoszcz, Poland, 8Medycyna Kliniczna Marzena Waszczak-Jeka, Warsaw, Poland, 9Reuma Centrum, Warsaw, Poland, 10Centrum Medyczne AMED oddzial w Łodzi, Łódź, Poland, 11University of Warmia and Mazury, Olsztyn, Poland, 12Medical University of Białystok and Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk, Białystok, Poland, 13Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, 14Celltrion, Inc., Incheon, Republic of Korea, 15Mount Sinai Hospital, Toronto, ON, Canada

    Background/Purpose: CT-P17 (100 mg/mL) is the first proposed biosimilar of the high concentration and citrate-free formulation of reference adalimumab. The purpose of this study was…
  • Abstract Number: 1348 • ACR Convergence 2020

    What Influence Do Clinical Domains Other Than Arthritis Have on Composite Clinical Outcomes in Psoriatic Arthritis?: Comparison of Treatment Effects in the SEAM-PsA Trial

    Philip Helliwell1, Philip Mease2, Arthur Kavanaugh3, Laura Coates4, Alexis Ogdie5, Atul Deodhar6, Vibeke Strand7, Ervant Maksabedian8, Gregory Kricorian9, Lyrica Liu9, David Collier10 and Dafna Gladman11, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 3UC San Diego Health System, San Diego, CA, 4University of Oxford, Oxford, United Kingdom, 5University of Pennsylvania, Philadelphia, PA, 6Oregon Health & Science University, Portland, OR, 7Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, 8Amgen Inc., LOS ANGELES, CA, 9Amgen Inc., Thousand Oaks, CA, 10Amgen, Thousand Oaks, CA, 11Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis is broadly characterized by clinical domains such as enthesitis, dactylitis, nail manifestations, and psoriasis.  How these clinical domains influence the response to…
  • Abstract Number: 2006 • ACR Convergence 2020

    Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data

    Markus Rehberg1, Clemens Giegerich1, Amy Praestgaard2, Hubert van Hoogstraten3, Melitza Iglesias-Rodriguez2, Jeffrey R Curtis4, Jacques-Eric Gottenberg5, Andreas Schwarting6, Santos Castañeda7, Andrea Rubbert Roth8 and Ernest Choy9, 1Sanofi, Frankfurt, Germany, 2Sanofi, Cambridge, MA, 3Sanofi, Bridgewater, NJ, 4Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 5Strasbourg University Hospital, Strasbourg, France, 6Johannes Gutenberg University, Mainz, Germany, 7Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 8Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, 9CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom

    Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
  • Abstract Number: 0354 • ACR Convergence 2020

    How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study

    Uta Kiltz1, Jan Brandt-Jürgens2, Peter Kästner3, Elke Riechers4, Daniel Peterlik5 and Hans-Peter Tony6, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Rheumatologische Schwerpunktpraxis Berlin, Berlin, Germany, 3Ambulantes Rheumazentrum, Erfurt, Germany, 4Hannover Medical School, Hannover, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany, 6Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

    Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology